文献速递慢性肾脏病遗传性与小管间质肾病

成人常染色体显性多囊肾病疾病严重程度的家族内变异

Familial Variability of Disease Severity in Adult Patients With ADPKD.
PubMed 文献 · Kidney Int Rep · 2023-12-12

该研究基于爱尔兰92个无亲缘关系的ADPKD家系(共292例患者)的临床与系谱数据,所有先证者均接受基因测序,采用肾衰竭发病年龄、eGFR下降、PROPKD评分及影像学标准评估疾病严重程度。至少13%的家系存在显著的家族内变异,且PKD1-NT变异家系比例更高;多变量混合效应模型显示肾脏生存的家族内变异独立于所测基因型因素(P<0.001)。

要点

  • 至少13%的ADPKD家系存在显著家族内疾病严重程度变异。
  • PKD1-NT变异家系中家族内变异比例更高。
  • 肾脏生存的家族内变异独立于所测预后相关基因型因素。

核心结论

  • 采用客观指标量化发现至少13%的ADPKD家系存在显著家族内表型变异,其机制尚不完全清楚。

研究设计与样本

  • 分析爱尔兰92个无亲缘关系ADPKD家系(共292例患者)的临床与系谱数据,所有先证者接受基因测序。

主要发现

  • 至少13%的92个家系存在显著家族内变异,PKD1-NT变异家系比例更高。
  • 在≥2名成员发生肾衰竭的家系中,家族内肾衰竭年龄平均差为7年,各等位基因组间无差异。
  • 预设标准显示家族内显著变异比例分别为:肾衰竭年龄7.7%、PROPKD评分8.4%、影像学标准24%。
  • 多变量混合效应模型显示肾脏生存的家族内变异独立于所测基因型因素(P<0.001)。

关键数值与推荐

  • 肾衰竭发病年龄、eGFR下降、PROPKD评分及影像学标准用于将疾病严重程度分为轻度、中度或重度。
  • 每家族中1例轻度和1例重度病例定义为显著家族内变异。

临床怎么用

  • 临床评估ADPKD患者预后时需考虑家族内变异,同一家系不同患者 severity 可能差异显著。

局限性

  • 家族内表型变异机制仍未完全阐明,需更全面识别相关临床与基因型因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic nephropathy and has striking familial variability of disease severity. METHODS: To better comprehend familial phenotypic variability, we analyzed clinical and pedigree data on 92 unrelated ADPKD kindreds with ≥2 affected individuals (N = 292) from an Irish population. All probands underwent genetic sequencing. Age at onset of kidney failure (KF), decline in estimated glomerular filtration rate (eGFR), predicting renal outcome in polycystic kidney disease (PROPKD) score, and imaging criteria were used to assess and grade disease severity as mild, intermediate, or severe. One mild and 1 severe case per family defined marked intrafamilial variability of disease severity. RESULTS: Marked intrafamilial variability was observed in at least 13% of the 92 families, with a higher proportion of families carrying PKD1-nontruncating (PKD1-NT) variants. In families with ≥2 members affected by KF, the average intrafamilial age difference was 7 years, and there was no observed difference in intrafamilial variability of age at KF between allelic groups. The prespecified criteria showed marked familial variability in 7.7%, 8.4%, and 24% for age at KF, the PROPKD score, and imaging criteria, respectively. In our multivariate mixed-effects model, the intrafamilial variability in kidney survival was independent of the measured genotypic factors associated with prognosis and survival (P = <0.001). CONCLUSION: Using objective measures, we quantified marked intrafamilial variability in ADPKD disease phenotype in at least 13% of families. Our findings indicate that intrafamilial phenotypic variability remains incompletely understood and necessitates a more thorough identification of relevant clinical and genotypic factors.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Elhassan EAE, O'Kelly P, Collins KE, et al. Familial Variability of Disease Severity in Adult Patients With ADPKD. Kidney Int Rep. 2023. PMID: 38481516. doi:10.1016/j.ekir.2023.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。